Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer : In response to: Dirk Böhmer and Arne Grün. Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer. by Jiang, Di Maria et al.
LETTER TO THE EDITOR
Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant
Chemotherapy and Trimodality Therapy in Selected Patients
with Muscle-Invasive Bladder Cancer
In response to: Dirk Böhmer and Arne Grün. Lacking Evidence to Recommend Neoadjuvant
Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer
Di Maria Jiang1 & Peter Chung2 & Girish S. Kulkarni3 & Nick D. James4,5 & Srikala S. Sridhar1
# The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021
Dear Editor,
Thank you for the opportunity to address the role of neo-
adjuvant chemotherapy (NAC) prior to bladder-sparing
trimodality therapy (TMT) for patients with muscle invasive
bladder cancer (MIBC), in response to the letter by colleagues
Böhmer and Grün. While we agree the role of NAC in this
setting is not clearly defined, there are several important rea-
sons for considering this treatment approach in select patients
who are planned for TMT.
Historically, TMT was reserved for the elderly and frail pa-
tients with MIBC who were ineligible for radical cystectomy
(RC). These patients were often also ineligible for cisplatin-
basedNAC due to significant comorbidities or poor performance
status. Thus, NACwas rarely used in historical TMT trials. In the
contemporary setting however, TMT is being increasingly uti-
lized as an accepted alternative to RC and in selected patients has
shown comparable long-term outcomes. There are now more
patients who are younger and fitter opting for TMT. [1].
Importantly these patients, unlike the older and frailer patients,
are more likely to be eligible for and tolerate NAC.
There is strong biological rationale and Level 1 evidence
supporting the use of NAC in MIBC. This is a highly chemo-
sensitive disease with a high propensity for distant relapse,
likely due to the presence of micrometastatic disease at presen-
tation. The goal of NAC prior either RC or TMT is essentially
similar—to eliminate micrometastatic disease and improve
cure rates. Cisplatin-based NAC has a pathologic complete
response (pCR) rate of about 30% which is strongly correlated
with improved overall survival (OS) [2].
The question remains, why would NAC improve OS in
patients treated with RC but not with TMT? According to the
landmark ABC meta-analysis, NAC has been shown to im-
prove OS, regardless of whether patients receive RC or radia-
tion [3]. In the large BC2001 phase III clinical trial evaluating
the added benefit of concurrent 5-fluorouracil plus mitomycin
to radiotherapy, the use of NAC did not impact the benefit of
concurrent chemotherapy [4]. While concurrent chemotherapy
improves local control, it did not improve metastasis-free sur-
vival or OS. This suggests that concurrent chemotherapy can-
not serve as a substitute for NAC and does not adequately
address the risk of micrometastases at presentation.
The BA06 30894 trial was a randomized phase III trial
which evaluated the benefit of cisplatin, methotrexate, and
vinblastine (CMV) NAC for 3 cycles prior to local definitive
therapy and accrued patients between 1989 and 1995. The
results showed that NAC reduced the risk of death by 26%
for patients who received RC and by 20% for patients who
received radiotherapy alone [5]. As Böhmer and Grün have
pointed out, statistical significance was seen in patients under-
going RC but was not seen among patients who received
radiotherapy; nevertheless, a strong trend in support of NAC
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was observed (p=0.070). There are also a number of important
caveats that warrant consideration. The BA06 30894 trial was
not designed to specifically evaluate the benefit of NAC in
either subgroup, but rather was powered to detect a 10% ben-
efit at 2 years across the whole study population. This degree
of benefit was not realized, as the initial report demonstrated
only a 5.5%OS improvement at 3 years. The updated analysis
after a median follow up of 8 years, however confirmed an
overall survival advantage [8]. To correctly interpret whether
the overall treatment effect is heterogenous across subgroups,
an interaction analysis should be used rather than the p value
[6]. Based on the results of their pre-planned (exploratory)
interaction analysis, “for overall survival, there was no evi-
dence to suggest that the effect of chemotherapy was more or
less for patients treated with cystectomy than for those treated
with radiotherapy” [7, 8]. As Böhmer and Grün acknowl-
edged, baseline characteristics were not well balanced be-
tween the RC and radiotherapy groups. This was expected
since the choice of local definitive therapy was not randomly
assigned. Patients in the radiotherapy arm were older, frailer,
and had more advanced disease, and were a different patient
population than patients who received RC. However in pa-
tients who were eligible to receive NAC, the benefit of NAC
is supported by the results of the interaction analysis [8]. With
respect to locoregional disease-free survival, the 9% improve-
ment in the radiotherapy subgroup compared with 26% in the
RC subgroup is hardly a surprising finding given that radio-
therapy alone and not concurrent chemoradiotherapy was
used in this trial. Concurrent chemoradiotherapy is now rec-
ognized as the standard of care for trimodality therapy and has
shown superior local control over radiotherapy alone based on
level I evidence [4].
In a Danish trial, the addition of 3 cycles of cisplatin-based
NAC to radiotherapy alone in 120 patients improved median
survival from 16.3 to 19.2 months, although statistical signifi-
cance was not reached likely due to inadequate sample size [9].
There is not yet any robust data evaluating the benefit of
NAC prior to radiotherapy concurrent with chemotherapy. As
discussed in our review, the Radiation Therapy Oncology
Group (RTOG) 89-03 phase III trial published in 1998 which
randomized patients to two cycles of neoadjuvant CMV
followed by TMT versus TMT alone was significantly under-
powered, with only 123 patients randomized. Thus, RTOG
89-03 cannot exclude the benefit of NAC prior to TMT given
its limited statistical power. At the time of trial conduct,
growth factor support and modern antiemetics were not yet
available, and completion rates for NAC were only 67%. We
recently published our center’s experience in using NAC prior
to TMT. Although many patients required dose adjustments,
completion rates of NAC were 95%. All patients completed
planned radiotherapy, and 84% completed at least 60% of
planned concurrent chemotherapy [10]. More modern trials
evaluating NAC also report favorable toxicity profiles, with
grade 3–4 toxicity of NAC between 10 and 15% [11, 12]. In
addition, RTOG 89-03 did not provide any evidence as to
whether three or four (instead of two) cycles of NAC can
improve cure rates. Therefore, no definitive conclusions can
be drawn from this trial.
Although, currently, no large randomized phase III trial has
been able to address this important question of whether there
is a benefit to NAC prior to TMT, the “lack” of evidence does
not necessarily imply lack of benefit. NAC continues to be
grossly underutilized in the treatment of MIBC and outcomes
remain suboptimal [13–15]. Administering NAC prior to
TMT in selected patients is a safe and feasible strategy which
has the potential to improve survival. Ongoing trials are al-
ready increasingly incorporating the use of NAC prior to
TMT, as we highlighted. In particular, the RETAIN bladder
phase II trial (NCT02710734) is evaluating a risk adapted
approach to help guide various bladder sparing strategies
based on response to NAC and tumor mutational profile.
The results of these trials are eagerly awaited to further define
the role of NAC prior to TMT in the genomic era.
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